Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30977019 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL30977011 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL30977034 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL8642161 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL490564 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL16175782 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL30977017 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL8772499 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL30977015 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTTMAPTTHRB | |
| SCHEMBL30977024 | 1.00 | MEN1 (0.48) | MEN1KMT2AHTTMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321329-A1 | FORMULATION FOR THE TREATMENT OF ACNE | AKZO NOBEL CHEMICALS INT BV (NL) | 2019-10-24 | — | — | US | disclosed |
| EP-3340975-B1 | FORMULATION FOR THE TREATMENT OF ACNE | AKZO NOBEL CHEMICALS INT BV (NL) | 2019-07-24 | — | — | EP | disclosed |
| US-10278945-B2 | Formulation for the treatment of acne | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2019-05-07 | — | — | US | disclosed |
| US-20190022050-A1 | FORMULATION FOR THE TREATMENT OF ACNE | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2019-01-24 | — | — | US | disclosed |
| EP-3340975-A1 | FORMULATION FOR THE TREATMENT OF ACNE | Akzo Nobel Chemicals International B.V. (NL) | 2018-07-04 | — | — | EP | disclosed |
| US-20170156999-A1 | PERSONAL CARE COMPOSITION IN A DISSOLVABLE CONTAINER | Henkel IP & Holding GmbH (DE) | 2017-06-08 | — | — | US | disclosed |
| WO-2017036897-A1 | FORMULATION FOR THE TREATMENT OF ACNE | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2017-03-09 | — | — | WO | disclosed |
| EP-2393469-B1 | Process of treating hair | RHODIA OPERATIONS (FR) | 2016-10-12 | — | — | EP | disclosed |
| EP-2419077-B1 | PROCESS OF TREATING DAMAGED HAIR | RHODIA OPERATIONS (FR) | 2016-10-12 | — | — | EP | disclosed |
| US-9072675-B2 | Non-irritating benzoyl peroxide | ESSENTIAL INGREDIENTS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-1663117-A1 | COSMETIC COMPOSITIONS IN SINGLE PORTION PACKAGINGS | Henkel Kommanditgesellschaft auf Aktien (DE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006018328-A2 | COMPACT HAIRSPRAY | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005060924-A1 | COSMETIC AGENTS PROVIDING VOLUME | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005060926-A1 | SPRAYABLE GEL | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2004100901-A2 | COSMETIC COMPOSITIONS IN SINGLE PORTION PACKAGINGS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1408912-A2 | TEMPERATURE INSENSITIVE ONE-PHASE MICROEMULSIONS | Dow Corning Corporation (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6645502-B2 | Pigmented composition for reducing shiny appearance of skin and cosmetically improving appearance of skin imperfections | REVLON CONSUMER PRODUCTS CORPORATION | 2003-11-11 | — | — | US | disclosed |
| WO-2003009819-A2 | TEMPERATURE INSENSITIVE ONE-PHASE MICROEMULSIONS | DOW CORNING CORPORATION (US) | 2003-02-06 | — | — | WO | disclosed |
| US-6498197-B1 | Temperature insensitive one-phase microemulsions | DOW CORNING CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-6485731-B2 | CONDITIONING NAILS OR SURROUNDING CUTICLE WITH A COMPOSITION THAT HAS < 5% OF A FLUORINATED SILICONE OIL | REVLON CONSUMER PRODUCTS CORPORATION | 2002-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321329-A1 | FORMULATION FOR THE TREATMENT OF ACNE | ACOX1, HSD17B12, ACOX3 | MEN1 3621/4885KMT2A 3955/4885HTT 3288/4885 |
| US-20190022050-A1 | FORMULATION FOR THE TREATMENT OF ACNE | ACOX1, HSD17B12, ACOX3 | MEN1 3621/4885KMT2A 3955/4885HTT 3288/4885 |
| US-10278945-B2 | Formulation for the treatment of acne | ACOX1, HSD17B12, ACOX3 | MEN1 3621/4885KMT2A 3955/4885HTT 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.